Prof. Konrad Rejdak comments on the halfway point of research into the use of amantadine in the treatment of COVID-19

Research on amantadine conducted by the team of prof. Konrad Rejdak are at the halfway point. "About 500 people in the most difficult pandemic period were consulted and sought medical help. It happened regardless of the clinical trial. We did it in the sense of the mission [...] We are glad that, under our care, the mortality rates among people at risk They are so small. I am asking experts who criticize the sense of conducting the study to take this aspect into account - we did it regardless of ABM funding, we helped patients and we will continue to do it "- comments the president of the Polish Neurological Society.